Work With Us
Contact Us
Work With Us
Contact Us
Search
Home
About Us
Our Mission and Vision
Meet the Team
Board of Directors
Scientific Advisory Board
Investors
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Clinical Trials
Publications
What’s New
Press Releases
Events
Home
About Us
Our Mission and Vision
Meet the Team
Board of Directors
Scientific Advisory Board
Investors
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Clinical Trials
Publications
What’s New
Press Releases
Events
December 9, 2024
CID-078, a first-in-class oral cyclin A/B-RxL inhibitor, elicits anti-tumor activity in breast cancer patient-derived xenograft models
Click the poster to download.
